Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Jan 08, 2025 (filed on Jan 29, 2025)Insider Name:Milligan SandraOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-6,356Price:$0.70
-
Dec 31, 2024 (filed on Jan 08, 2025)Insider Name:Ragard John PhillipOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,844Price:--
-
Dec 31, 2024 (filed on Jan 08, 2025)Insider Name:Ragard John PhillipOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:4,844Price:--
-
Dec 31, 2024 (filed on Jan 08, 2025)Insider Name:Parnell WinfredOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-5,157Price:--
-
Dec 31, 2024 (filed on Jan 08, 2025)Insider Name:Parnell WinfredOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:5,157Price:--
-
Dec 31, 2024 (filed on Jan 08, 2025)Insider Name:Herchuk Jannie PrestridgeOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-8,437Price:--
-
Dec 31, 2024 (filed on Jan 08, 2025)Insider Name:Herchuk Jannie PrestridgeOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:8,437Price:--
-
Dec 31, 2024 (filed on Jan 08, 2025)Insider Name:Fralick Celeste RachelleOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-5,000Price:--
-
Dec 31, 2024 (filed on Jan 08, 2025)Insider Name:Fralick Celeste RachelleOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:5,000Price:--
-
Dec 31, 2024 (filed on Jan 29, 2025)Insider Name:Milligan SandraOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:20,000Price:--
Filings by filing date
-
Dec 31, 2024 (filed on Jan 29, 2025)Insider Name:Milligan SandraOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:20,000Price:--
-
Jan 08, 2025 (filed on Jan 29, 2025)Insider Name:Milligan SandraOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-6,356Price:$0.70
-
Dec 31, 2024 (filed on Jan 29, 2025)Insider Name:Milligan SandraOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:20,000Price:--
-
Dec 31, 2024 (filed on Jan 08, 2025)Insider Name:Ragard John PhillipOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,844Price:--
-
Dec 31, 2024 (filed on Jan 08, 2025)Insider Name:Ragard John PhillipOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:4,844Price:--
-
Dec 31, 2024 (filed on Jan 08, 2025)Insider Name:Parnell WinfredOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-5,157Price:--
-
Dec 31, 2024 (filed on Jan 08, 2025)Insider Name:Parnell WinfredOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:5,157Price:--
-
Dec 31, 2024 (filed on Jan 08, 2025)Insider Name:Herchuk Jannie PrestridgeOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-8,437Price:--
-
Dec 31, 2024 (filed on Jan 08, 2025)Insider Name:Herchuk Jannie PrestridgeOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:8,437Price:--
-
Dec 31, 2024 (filed on Jan 08, 2025)Insider Name:Fralick Celeste RachelleOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-5,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 12117 Bee Caves Road Building Three Suite 100 AUSTIN TX 78738 |
Tel: | N/A |
Website: | https://aspirawh.com |
IR: | See website |
Key People | ||
Sandra Milligan President | Michael Buhle Chief Executive Officer, Chief Commercial Officer | James Crawford Principal Financial Office, Principal Accounting Officer, Vice President - Finance |
Business Overview |
Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus workflow is designed to assess the risk of ovarian malignancy in women planning for surgery and uses two tests, Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Its in-development test pipeline includes OvaMDxSM risk assessment, EndoCheck and EndoMDx, which are designed to expand its ovarian cancer portfolio and address the tremendous need for noninvasive diagnostics for endometriosis. EndoCheck is a noninvasive test designed to identify endometriomas. |
Financial Overview |
For the nine months ended 30 September 2024, Aspira Women's Health Inc revenues decreased 3% to $6.8M. Net loss decreased 14% to $11.7M. Revenues reflect Genetics decrease from $1K to $0K. Lower net loss reflects Change in fair value of warrant liabilit increase from $233K (expense) to $1.3M (income), General and administrative decrease of 15% to $7.3M (expense), General and administrative decrease of 46% to $556K (expense). |
Employees: | 64 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $3.36M as of Sep 30, 2024 |
Annual revenue (TTM): | $8.96M as of Sep 30, 2024 |
EBITDA (TTM): | -$16.87M as of Sep 30, 2024 |
Net annual income (TTM): | -$14.80M as of Sep 30, 2024 |
Free cash flow (TTM): | -$14.59M as of Sep 30, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 16,667,255 as of Nov 18, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |